Caribou Biosciences Appoints Dr. Natalie Sacks to Board of Directors
Caribou Biosciences, Inc., a leading genome editing company, announced today that it has appointed Natalie Sacks, MD to its Board of Directors. Dr. Sacks is an accomplished industry leader and oncology expert who has played a key role in the development and approval of several oncology therapeutics.
“We are excited to welcome Dr. Sacks to our Board of Directors,” said Rachel Haurwitz, PhD, President and Chief Executive Officer of Caribou. “Her strong record of achievements at both large and small companies is a valuable addition to our Board’s expertise. We look forward to capitalizing on her experience and insights as we continue our advancement of multiple therapeutic categories.”
Dr. Sacks is currently the Chief Medical Officer at Harpoon Therapeutics, focused on the development of novel T cell therapeutics. Dr. Sacks previously served as Chief Medical Officer at Aduro Biotech, a company focused on the advancement of novel immuno-oncology technologies. She also served as Vice President of Clinical Development at Onyx Pharmaceuticals (acquired by Amgen) where she played a key role in business development efforts along with the development and approval of Kyprolis.® She also previously served as Vice President of Clinical Research for Exelixis where she directed the development of a portfolio of small molecules, including the late-stage development of Cometriq.® Earlier in her career, Dr. Sacks served as Vice President of Clinical Development at Cell Genesys, a company focused on the development of cancer vaccines and engineered chimeric antigen receptor (CAR) T cells. Dr. Sacks was an Assistant Clinical Professor at the University of California, San Francisco, and served as volunteer Attending Physician in Hematology-Oncology at San Francisco General Hospital for more than a decade.
Dr. Sacks currently serves on the Board of Directors at Zymeworks, Inc. She received her MD from the University of Pennsylvania School of Medicine, her MS in Biostatistics from Harvard University School of Public Health, and her BA in Mathematics from Bryn Mawr College.
“I am delighted to be joining Caribou’s Board of Directors at this exciting inflection point in the company’s evolution,” remarked Dr. Sacks. “Caribou’s revolutionary gene editing technologies have the potential to usher in transformative therapies for diseases with clear unmet medical needs and I am excited to play a role in helping the company realize the full potential of these technologies.”
Dr. Sacks joins existing Board of Directors members Philip Austin, Founding Partner of Anterra Capital; Robert Weisskoff, a Partner at F-Prime Capital; and Dr. Haurwitz.
About Caribou Biosciences, Inc.
Caribou is a leading company in CRISPR genome editing founded by pioneers of CRISPR-Cas9 biology. Caribou’s proprietary technologies put the company at the forefront of the development of new medical therapies. The company is focused on the development of an internal pipeline of off-the-shelf CAR-T therapies and engineered gut microbes.
Additionally, Caribou offers licenses to its CRISPR-Cas9 foundational IP in multiple fields including research tools, internal research use, diagnostics, and industrial biotechnology. Interested companies may contact Caribou at firstname.lastname@example.org.
For more information about Caribou, visit www.cariboubio.com and follow the Company @CaribouBio. “Caribou Biosciences” and the Caribou logo are registered trademarks of Caribou Biosciences, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181212005104/en/